The chloroplast division protein FtsZ is encoded by a nucleomorph gene in cryptomonads.

Mol Gen Genet

Abteilang für Zellbiologie und Angewandte Botanik, Philipps-Universität Marburg, Germany.

Published: November 1998

Guillardia theta is a cryptomonad alga, whose phototrophic symbiont was acquired by secondary endocytobiosis. The nucleomorph, the vestigial nucleus of the eukaryotic endosymbiont, harbors three linear chromosomes with a total coding capacity of 515 kb. Sequencing of the nucleomorph genome reveals that it encodes an ORF homologous to the bacterial cell division protein FtsZ, supporting the hypothesis that FtsZ is common in chloroplasts. We show that the nucleomorph-encoded ftsZ gene is transcribed. The transcript is polyadenylated and therefore shows features typical of eukaryotic transcripts. However, 3' processing of nucleomorph mRNA is inaccurate. Transcripts of nucleomorph genes in G. theta overlap with neighboring UTRs and coding regions. We demonstrate that the reading frame encoding NmFtsZ is not interrupted by introns. Subcellular localization of the protein reveals that FtsZ is localized exclusively in the chloroplast of G. theta, demonstrating that FtsZ is imported into the organelle.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s004380050887DOI Listing

Publication Analysis

Top Keywords

division protein
8
protein ftsz
8
ftsz
6
nucleomorph
5
chloroplast division
4
ftsz encoded
4
encoded nucleomorph
4
nucleomorph gene
4
gene cryptomonads
4
cryptomonads guillardia
4

Similar Publications

While durable antibody responses from long-lived plasma cell (LLPC) populations are important for protection against pathogens, LLPC may be harmful if they produce antibodies against self-proteins or self-nuclear antigens as occurs in autoimmune diseases such as systemic lupus erythematosus (SLE). Thus, the elimination of autoreactive LLPC may improve the treatment of antibody-driven autoimmune diseases. However, LLPC remain a challenging therapeutic target.

View Article and Find Full Text PDF

Background: Despite advancements in the therapeutic armamentarium for Crohn's disease (CD), biologic and small molecule monotherapies are associated with sub-optimal response and remission rates. Utilizing dual biologic therapy (DBT) holds the potential to increase efficacy in the treatment of refractory or partially responsive CD. Evidence pertaining to this strategy remains limited.

View Article and Find Full Text PDF

Studies on the nutritional strength of various hyacinth bean varieties for their potential utilization as promising legume.

J Food Sci Technol

January 2025

Grain Science and Technology Division, Defence Food Research Laboratory, Mysore, Karnataka 570011 India.

This study aimed to compare thirteen different varieties of hyacinth beans analyzedfor their nutritional and antinutritional constituents. The study classified HA-3, HA-4, and Kadale Avare as Lignosus varieties, while the remaining varieties Arka, Pusa, CO, and NS, were classified as Typicus. The protein content ranged from 19.

View Article and Find Full Text PDF

An approach to predict and inhibit Amyloid Beta dimerization pattern in Alzheimer's disease.

Toxicol Rep

June 2025

Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, West Bengal 700054, India.

Alzheimer's Disease (AD) is one of the leading neurodegenerative diseases that affect the human population. Several hypotheses are in the pipeline to establish the commencement of this disease; however, the amyloid hypothesis is one of the most widely accepted ones. Amyloid plaques are rich in Amyloid Beta (Aβ) proteins, which are found in the brains of Alzheimer's patients.

View Article and Find Full Text PDF

Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites.

Mol Ther Methods Clin Dev

March 2025

Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA.

Lipid nanoparticles (LNPs) are often liver tropic, presenting challenges for LNP-delivered mRNA therapeutics intended for other tissues, as off-target expression in the liver may increase side effects and modulate immune responses. To avoid off-target expression in the liver, miR-122 binding sites have been used by others in viral and non-viral therapeutics. Here, we use a luciferase reporter system to compare different copy numbers and insertion locations of miR-122 binding sequences to restrict liver expression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!